Navigation Links
Data in NEJM shows Novartis drug Signifor® is first therapy to provide rapid, durable benefit for Cushing's disease patients in Phase III study
Date:3/7/2012

Patients with primarily moderate to severe hypercortisolism were randomized to receive pasireotide sc injection in doses of 900 micrograms (n=80) or 600 micrograms (n=82) twice daily. The primary endpoint was the proportion of patients who achieved normalization of UFC after six months without dose up-titration relative to randomized dose. The primary endpoint was met in patients treated with 900 microgram sc twice daily. Secondary endpoints included safety, proportion of patients with UFC </= ULN at months 3, 6 and 12 regardless of dose titration, proportion of patients with partial UFC control (defined as UFC > ULN and >/= 50% reduction from baseline); changes from baseline in plasma adrenocorticotropic hormone (ACTH), UFC, serum and salivary cortisol over time and changes from baseline in clinical signs, symptoms and health-related quality of life(1).

After six months, the primary efficacy responder rate was 26.3% (95% confidence interval [CI], 16.6 to 35.9) and 14.6% (95% CI, 7.0 to 22.3), respectively, for the 900 microgram and 600 microgram groups. Based on pre-specified criteria (lower bound of 95% CI >15%), the 900 microgram group met the primary endpoint and the 600 microgram group did not meet the primary endpoint. After 12 months, the proportion of responders regardless of dose up-titration was 25.0% and 13.4%, respectively, for the 900 microgram and 600 microgram groups. The median reduction in UFC after six months was 47.9% for both groups. The median reduction in UFC after 12 months was 62.4% (900 microgram) and 67.6% (600 microgram). In patients with full or partial control of UFC levels at months 1 or 2, 71.4% remained on treatment until month 12 compared with 24.6% of those uncontrolled at months 1 and 2(1).

Adverse events associated with cortisol levels below the normal range were experienced by 13 patients. This was managed by dose reduction without loss of efficacy. There were no deaths during pasireotide treatme
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
3. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
6. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
7. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
8. Feeling Anxious or Distracted? New Research Shows a Cup of Tea Could Help
9. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
10. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
11. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... March 26, 2015 "Whether it,s our family, ... day." In a single sentence, Dr. ... officer at Pfizer,s Centers for Therapeutic Innovation ... fueling progress at America,s biopharmaceutical companies. ... with academia, patient foundations and the National Institutes of ...
(Date:3/26/2015)... 2015 Cardiologists at Beaumont Hospital, ... commercial implant of a device recently approved by the ... fibrillation. The Watchman Left Atrial Appendage Closure implant is ... to reduce the risk of stroke. Atrial ... more than 5 million Americans. Twenty percent of all ...
(Date:3/26/2015)... NORTH CHARLESTON, S.C. , March 26, 2015 ... issues and were told by their existing PACS vendor ... Memorial Hospital (CMH) determined that they needed a ... Clinch Memorial Hospital selected Avreo interWORKS due to ... that carries modern meaningful use standards through to ...
Breaking Medicine Technology:Collaboration for Cures: Teaming Up to Advance Science and Save Lives 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 3Clinch Memorial Hospital Modernizes Workflow with Avreo interWORKS 2
... CITY, Calif., Nov. 12, 2010 AcelRx Pharmaceuticals, Inc. announced ... S-1 with the U.S. Securities and Exchange Commission (SEC) relating ... common stock. All shares of the common stock to be ... Piper Jaffray & Co. is acting as sole ...
... FARMINGDALE, N.Y., Nov. 12, 2010 Misonix, Inc. (Nasdaq: ... the art, ultrasonic medical device technology, which worldwide is ... for the first fiscal quarter ending September 30, 2010. ... and Richard Zaremba, Senior VP and Chief Financial Officer, ...
Cached Medicine Technology:Misonix Reports First Quarter Fiscal 2011 Financial Results 2Misonix Reports First Quarter Fiscal 2011 Financial Results 3Misonix Reports First Quarter Fiscal 2011 Financial Results 4Misonix Reports First Quarter Fiscal 2011 Financial Results 5Misonix Reports First Quarter Fiscal 2011 Financial Results 6
(Date:3/27/2015)... The 2015 Deep Market Research Report ... in-depth study on the current state of the ... on the Chinese situation. , The report provides ... classifications, applications and industry chain structure. The Glutathione ... and Chinese domestic situations including development trends, competitive ...
(Date:3/27/2015)... Canadian Cannabis Clinics ( http://www.cannabisclinics.ca ), Canada’s ... medical cannabis as a treatment for patients has ... dedicated to providing access to safe medical marijuana ... searching for medical marijuana treatment in legal medical ... domain for Canada. , With the partnership ...
(Date:3/27/2015)... “ VXi BlueParott Reveal ” was ... Report, which features the latest and coolest technology products ... special reporter for NewsWatch, conducted the review and shared ... eliminating 90% of ambient noise. , Today, business is ... are important to any professional, voice calls are just ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 In light ... (case number 1:15-cv-10429, U.S. District Court, District of Massachusetts; ... the Eastern District of Pennsylvania), the San Diego personal ... Helbock, A.P.C. are announcing that they are available to ... of women who were prescribed Zofran while pregnant and ...
(Date:3/26/2015)... Elfster.com, the top-rated Secret Santa generator, is proud ... capabilities to its leading Secret Santa list technology. A ... one creates of things to do before one dies, ... name. Nowadays many millennials are creating summer bucket ... , "We are greatly expanding our technology to new ...
Breaking Medicine News(10 mins):Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 2Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 3Health News:Canadian Cannabis Clinics (CCC) to Join the Canada.MarijuanaDoctors.com Network 2Health News:A Device to Tune out Background Noise was Recently Featured on NewsWatch Television 2Health News:The Law Office of Melinda J. Helbock, A.P.C. Announces That It Is Now Accepting Case Reviews for Potential Zofran Birth Defect Lawsuits 2Health News:Plans for Bucket List Generator - Just In Time for Summer - Announced by Elfster 2
... 9 ULURU Inc. (NYSE Alternext: ULU) today announced the ... the Company effective immediately. Following his resignation as Chief ... Director of the Company.Renaat Van den Hooff has been appointed ... President and Chief Executive Officer. Mr. Van de Hooff ...
... /PRNewswire/ -- SecureWorks(R), one of the ... with Columbian-based ETEK International to extend its security services ... One of South America,s leading security providers, ETEK will ... include, among others, Intrusion Prevention and Detection, Security and ...
... March 9 Based on its recent analysis ... Sullivan recognizes ValveXchange, Inc. with the 2009 North ... Year Award for developing the innovative ValveXchange Heart ... valve, the patented system promises to mitigate the ...
... March 9 ProteoTech Inc. announced today that ... Dr. Luke Esposito, Director of In Vitro Screening, ... Parkinson,s Diseases, to be held in Prague, Czech Republic, March ... Snow will give an oral presentation discussing promising results pertaining ...
... Tenn., March 9 Brookdale Senior Living Inc. ... Bill Sheriff, Chief Executive Officer, and Mark Ohlendorf, Co-President ... the Company at the Barclays Capital Global Healthcare Conference ... beginning at 4:15 p.m. Eastern Time.The presentation is being ...
... March 9 DURECT Corporation (Nasdaq: DRRX ... will be presenting at the Cowen and Company 29th ... a.m. EDT. The conference is being held at ... live audio webcast of the presentation will be available ...
Cached Medicine News:Health News:ULURU Inc. Announces Senior Management Change 2Health News:SecureWorks Partners With ETEK International to Provide Security Services to the South American and Latin American Markets 2Health News:Frost & Sullivan Recognizes ValveXchange's Pioneering Heart Valve Technology for Unique Long-term Management and Future Replacement Advantages 2Health News:Frost & Sullivan Recognizes ValveXchange's Pioneering Heart Valve Technology for Unique Long-term Management and Future Replacement Advantages 3Health News:Frost & Sullivan Recognizes ValveXchange's Pioneering Heart Valve Technology for Unique Long-term Management and Future Replacement Advantages 4Health News:Frost & Sullivan Recognizes ValveXchange's Pioneering Heart Valve Technology for Unique Long-term Management and Future Replacement Advantages 5Health News:ProteoTech to Present at 9th International Conference for Alzheimer's and Parkinson's Disease - Prague, Czech Republic, March 11-15, 2009 2Health News:DURECT to Participate in Cowen and Company Healthcare Conference 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: